Suchergebnisse - "Liu, Xiaoqing"

PubPharm (31)

1

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations : A Phase 1 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2024

von Duan, J. | Wu, L. | Yang, K. | +32

2

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

enthalten in: The New England journal of medicine | 2023

von Tsuboi, M. | Herbst, R. | John, T. | +118

CommentIn: Nat Rev Clin Oncol. 2023 Aug;20(8):504. - PMID 37311902

3

Safety and Efficacy of Epitinib for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases : Open-Label Multicentre Dose-Expansion Phase Ib Study

enthalten in: Clinical lung cancer | 2022

von Zhou, Q. | Wang, M. | Zhang, H. | +5

4

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC : Final Analysis, with a Focus on Patients Enrolled at Sites in China

enthalten in: Targeted oncology | 2022

von Tu, H. | Feng, J. | Shi, M. | +26

5

Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC : a multicenter phase-II trial

enthalten in: Signal transduction and targeted therapy | 2021

von Jiang, T. | Wang, P. | Zhang, J. | +22

6

Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE) : a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Respiratory medicine | 2021

von He, J. | Su, C. | Liang, W. | +30

7

Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer : Results from a randomized, open-label, phase 3 trial (ARCHER 1050)

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2021

von Cheng, Y. | Mok, T. | Zhou, X. | +17

8

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study) : an open-label, phase 1b/2, multicentre, randomised trial

enthalten in: The Lancet. Respiratory medicine | 2020

von Wu, Y. | Cheng, Y. | Zhou, J. | +69

CommentIn: Lancet Respir Med. 2020 Nov;8(11):1068-1070. - PMID 32479793

9

CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo

enthalten in: Thoracic cancer | 2020

von Zhang, K. | Wang, L. | Wei, A. | +2

10

Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor-tyrosine kinase inhibitor therapy

enthalten in: Thoracic cancer | 2020

von Lv, P. | Yang, S. | Liu, W. | +6